Dr. Seth Snyder focuses on preparing and prosecuting domestic and foreign patent applications in various technical areas, including medicinal and process chemistry, biotechnology, antibodies, immunotherapy, oncology, gene therapy, materials chemistry, drug delivery, diagnostics, batteries, and alternative fuels.

Seth has experience overseeing patent portfolios for international, midsize, and startup companies and advises biotechnology, pharmaceutical, and university clients on lifecycle management of marketed drug products and clinical candidates. In particular, Seth advises clients developing portfolios around small molecule therapeutics, monoclonal antibodies, biofuels, and personalized medicine. He also performs due diligence reviews of patent portfolios in transactions, including public offerings and acquisitions.

In addition, Seth provides litigation support, including invalidity and noninfringement analyses, freedom-to-operate (FTO), clearance, and invalidity searches, and patent portfolio landscape analyses. He also assists petitioners and patent owners in inter partes review (IPR) and reexamination proceedings before the Patent Trial and Appeal Board (PTAB).

Prior to working in private practice, Seth spent several years in academia, including at the University of Pennsylvania, School of Medicine, where he was an NIH Postdoctoral Fellow designing and synthesizing potential drug candidates and developing new synthetic methods. Seth is also a named inventor on several U.S. patents and published applications.

Seth received his Ph.D. in organic chemistry/chemical engineering from the University of Illinois at Urbana-Champaign, where he developed methods to perform enantioselective reactions using a novel two-component catalytic process. He earned his B.S. in chemical engineering, magna cum laude, from the Cooper Union for the Advancement of Science and Art.

Seth is registered to practice before the USPTO.